TRPV1 (Transient Receptor Potential Vanilloid 1) is a polymodal, non-selective cation channel expressed primarily on nociceptive C-fibres and A-delta fibres, as well as leukocytes, mast cells, and keratinocytes, that integrates thermal (>43°C), chemical (capsaicin, protons, oxylipins), and inflammatory signals into a unified pain and inflammatory response. It serves as a critical evolutionary sensor for tissue damage, linking dietary fatty acid composition, metabolic inflammation, and chronic pain syndromes.
Think of TRPV1 as the fire alarm in a kitchen. It's wired to detect multiple types of danger: smoke (heat >43°C), chili pepper vapors (capsaicin), vinegar fumes (acidosis/protons), and even the smell of burning grease (oxylipins from oxidized omega-6 fats). When any of these triggers reach threshold, the alarm blares—not with sound, but with Ca²⁺ flooding into the nerve cell, triggering the release of distress signals (Substance P, CGRP). Here's where it gets interesting: if you repeatedly blast the alarm with extremely high doses of chili vapor (high-dose capsaicin therapy), the alarm's battery drains and it goes silent for weeks (desensitization/defunctionalization). But if you constantly cook with rancid omega-6 oils, those oxidized fumes (oxylipins) keep the alarm hypersensitive—it starts going off even when there's no real fire (allodynia, peripheral neuropathy). Meanwhile, inflammatory messengers like NGF literally install more alarms and make them more sensitive (upregulation via TrkA Receptor). The modern Western diet, loaded with linoleic acid, is like leaving oxidized oil vapors constantly circulating—the alarm system never resets, creating chronic pain even without injury.
TRPV1 channel activation occurs through multiple converging mechanisms:
Thermal activation: Heat >43°C directly causes conformational change in the channel's transmembrane domains S5-S6, opening the central pore.
Vanilloid activation: Capsaicin and anandamide bind to an intracellular site between transmembrane domains 2-4, stabilizing the open state.
Proton activation: Extracellular acidification (pH <6.0) protonates residues E600 and E648, lowering activation threshold → enhanced channel opening even at body temperature (37°C).
Oxylipin activation: Omega-6 PUFA-derived oxylipins (especially 9-HODE, 13-HODE, 12,13-diHOME) activate TRPV1 through direct binding and membrane incorporation:
graph TD
A[Dietary linoleic acid] --> B[Membrane phospholipid incorporation]
B --> C[PLA2G7 cleavage]
C --> D[Oxidized linoleic acid metabolites]
D --> E[9-HODE, 13-HODE, 12,13-diHOME]
E --> F[TRPV1 activation]
F --> G["Ca²⁺ influx"]
G --> H[Neuropeptide release]
H --> I["Substance P + CGRP"]
I --> J[Neurogenic inflammation]
K[NGF from inflammation] --> L[TrkA receptor]
L --> M["PI3K/Akt + MAPK/ERK"]
M --> N["TRPV1 gene transcription ↑"]
M --> O["TRPV1 membrane insertion ↑"]
M --> P[PKC-mediated phosphorylation]
P --> Q[Sensitization - lower threshold]
Inflammatory sensitization cascade:
NGF → TrkA Receptor → PI3K + PKA + PKC → TRPV1 phosphorylation at S502, S800 → thermal threshold drops from 43°C to 35-37°C (body temperature now activates channel)
Bradykinin → B2 receptor → PKC activation → TRPV1 sensitization
PGE2 → EP receptors → PKA activation → TRPV1 sensitization
ATP → P2Y receptors → PKC → TRPV1 sensitization
Channel opening → non-selective cation influx (primarily Ca²⁺) → membrane depolarization → action potential propagation to dorsal root ganglia and dorsal horn
Ca²⁺ influx triggers vesicular release:
High-dose capsaicin (>1 mM for >30 min) → sustained Ca²⁺ influx → Ca²⁺-dependent:
- Calcineurin activation → TRPV1 dephosphorylation
- Calpain activation → TRPV1 proteolytic cleavage
- Mitochondrial dysfunction → ATP depletion → impaired vesicle recycling
- Nerve terminal retraction (reversible defunctionalization)
- Substance P depletion
Result: Profound hypoalgesia lasting weeks to months (therapeutic window for chronic pain syndromes).
High omega-6 to omega-3 ratio (typical Western diet: 15-20:1) → excessive arachidonic acid and linoleic acid in neuronal membranes → PLA2G7 (lipoprotein-associated phospholipase A2) cleavage → oxidized linoleic acid metabolites (oxylipins):
Omega-3 PUFAs (EPA, DHA) → competitive membrane incorporation → reduced substrate for oxylipin production → decreased TRPV1 activation
Selfish Systems Perspective: TRPV1 represents the Selfish Immune System's sensor network within nociceptors. The channel prioritizes inflammatory signaling over pain resolution, creating a vicious cycle where immune activation (via NGF, Prostaglandins) further sensitizes pain sensors, which release more pro-inflammatory neuropeptides (Substance P, CGRP). This creates chronic pain as a metabolic strategy—forced rest to conserve resources during perceived threat.
Evolutionary Mismatch: TRPV1 evolved to detect acute tissue damage (heat, acid, pathogens). The modern Western diet's omega-6 to omega-3 ratio (15-20:1 vs ancestral 1-2:1) creates constant oxylipin-mediated activation—an evolutionary mismatch where the alarm system interprets dietary composition as chronic injury. This manifests as peripheral neuropathy, fibromyalgia, chronic pain syndromes without structural damage.
Metamodel 1 - Chronic Low-Grade Inflammation: Dietary linoleic acid → oxylipins → TRPV1 activation → neurogenic inflammation → tissue inflammation → more NGF → more TRPV1 sensitization. This feed-forward loop exemplifies metaflammation.
Metamodel 5 - Gut-Brain Axis: TRPV1 is expressed on enteroendocrine cells and enteric nervous system neurons. Gut dysbiosis → increased LPS → TLR4 activation → PGE2 production → TRPV1 sensitization in gut neurons → Visceral Hypersensitivity in IBS. Bile acids (via TGR5) and SCFAs can modulate TRPV1 expression and function.
¶ Clinical Thresholds and Biomarkers
High TRPV1 relevance:
Dietary interventions (first-line in cPNI):
- Reduce linoleic acid: eliminate seed oils, processed foods
- Increase Omega-3 (EPA/DHA): target 2-4g/day → competitive membrane incorporation
- Target omega-6 to omega-3 ratio <4:1, ideally 2:1
- Monitor plasma oxylipins if available
- Time course: 6-12 months for complete neuronal membrane phospholipid turnover
Pharmacological targeting:
- High-dose capsaicin patches (8%): deplete Substance P, defunctionalize TRPV1 → indicated for post-herpetic neuralgia, peripheral neuropathy
- Oral capsaicin: gradual desensitization protocol (start 0.25mg, titrate to tolerance)
- Darapladib (experimental): PLA2G7 inhibitor → reduces oxylipin production
- TRPV1 antagonists (abandoned due to dangerous hyperthermia)
Contraindications for high-dose capsaicin:
- Active skin infection
- Cardiovascular instability (transient hypertension during application)
- Pregnancy (theoretical risk)
Monitoring efficacy:
- Quantitative sensory testing: thermal pain threshold (should increase from ~37°C toward normal 43°C)
- intraepidermal nerve fibre density (skin punch biopsy): expect stabilization or modest recovery
- Pain scores (NRS, VAS): expect 30-50% reduction by 3 months with dietary optimization
- TRPV1 activation threshold: heat >43°C, but sensitization by inflammation drops this to 35-37°C (body temperature)
- Non-selective cation channel: permeable to Ca²⁺, Na⁺, Mg²⁺ (PCa:PNa ≈ 10:1)
- Expression: predominantly C-fibres and A-delta fibres in dorsal root ganglia, also leukocytes, mast cells, keratinocytes, enterocytes
- Capsaicin EC50: ~700 nM (activating concentration)
- High-dose capsaicin (8% patch): 30-60 minutes application → 12 weeks analgesia
- Oxylipins from omega-6: 9-HODE, 13-HODE, 12,13-diHOME are endogenous TRPV1 agonists
- NGF-mediated upregulation: increases TRPV1 mRNA 3-5 fold within 24 hours via TrkA Receptor → ERK1-2 → transcription
- Western diet omega-6 to omega-3 ratio (15-20:1) vs optimal (1-2:1) drives chronic TRPV1 activation
- intraepidermal nerve fibre density: normal >13 fibers/mm; <5 fibers/mm indicates small fiber neuropathy with TRPV1+ fiber loss
- TRPV1 knockout mice show reduced inflammatory pain but normal acute nociception (other channels compensate)
- Anandamide (endocannabinoid) is endogenous TRPV1 agonist (dual CB1/TRPV1 activity)
- Proton sensitivity: pH <6.0 activates, pH 5.0-5.5 typical in inflammatory exudate
- Desensitization requires sustained Ca²⁺ influx: calcineurin activation + calpain-mediated degradation
- TRPV1 is target of PLA2G7 inhibitor darapladib to reduce oxylipin-mediated activation in clinical trials
- capsaicin — exogenous vanilloid agonist from chili peppers; high-dose causes therapeutic desensitization via sustained Ca²⁺ influx and Substance P depletion
- oxylipins — omega-6 PUFA oxidation products (9-HODE, 13-HODE, 12,13-diHOME) that directly activate TRPV1, causing diet-induced neuropathic pain
- PLA2G7 — lipoprotein-associated phospholipase A2 that cleaves membrane phospholipids to generate TRPV1-activating oxylipins
- linoleic acid — dietary omega-6 PUFA that accumulates in neuronal membranes, serving as substrate for oxylipins via PLA2G7
- omega-6 to omega-3 ratio — dietary ratio determining membrane phospholipid composition and oxylipin production; high ratio (>10:1) drives TRPV1 hyperactivation
- NGF — neurotrophin that upregulates TRPV1 expression and sensitizes existing channels via TrkA Receptor → PI3K/Akt and MAPK/ERK pathways
- TrkA Receptor — high-affinity NGF receptor mediating TRPV1 upregulation and phosphorylation-based sensitization
- Substance P — 11-amino-acid Neuropeptide released upon TRPV1 activation; binds NK1 receptors to cause neurogenic inflammation, plasma extravasation, mast cell degranulation
- CGRP — 37-amino-acid Neuropeptide co-released with Substance P from TRPV1+ neurons; potent vasodilator and immune cell activator in neurogenic inflammation
- peripheral neuropathy — loss of intraepidermal nerve fibre density caused by chronic TRPV1 activation from dietary oxylipins, metabolic dysfunction, or chemotherapy
- dorsal root ganglia — location of TRPV1-expressing nociceptive neuron cell bodies (C-fibre and A-delta populations)
- neurogenic inflammation — tissue inflammation initiated by Substance P and CGRP release from TRPV1-activated sensory neurons, independent of immune cell infiltration
- Bradykinin — inflammatory mediator that sensitizes TRPV1 via B2 receptor → PKC → channel phosphorylation, lowering activation threshold
- PGE2 — COX-2 product that sensitizes TRPV1 via EP receptor → PKA → phosphorylation at S116; central to inflammatory hyperalgesia
- anandamide — endocannabinoid that functions as dual CB1 agonist and TRPV1 agonist; produced during inflammation and stress
- darapladib — experimental PLA2G7 inhibitor designed to reduce oxylipin production and TRPV1-mediated neuropathic pain
- Calcium — primary cation flowing through TRPV1; Ca²⁺ influx triggers vesicular Neuropeptide release and, at high sustained levels, causes channel desensitization
- chronic pain syndromes — conditions like fibromyalgia, CRPS, Chronic fatigue syndrome characterized by TRPV1 sensitization and central sensitization
- central sensitization — spinal cord hyperexcitability driven by persistent TRPV1-mediated glutamate and Substance P release from primary afferents
- C tactile fibres — unmyelinated nociceptive fibers expressing high TRPV1 density; conduct slow burning pain signals
- A-delta fibres — thinly myelinated nociceptors with TRPV1 expression; mediate fast, sharp pain
- mast cells — tissue-resident immune cells expressing TRPV1; activation by oxylipins or capsaicin causes histamine and inflammatory mediator release
- neuropathic pain — pathological pain arising from nerve damage or dysfunction; TRPV1-mediated via oxylipin activation or inflammatory sensitization
- diet — dietary fatty acid composition directly determines neuronal membrane phospholipid profile and oxylipin production capacity
- Inflammation — tissue inflammatory state upregulates NGF, PGE2, Bradykinin, creating feed-forward sensitization of TRPV1
- PKC — protein kinase C isoforms phosphorylate TRPV1 at S502 and S800, lowering thermal threshold from 43°C to 35-37°C
- PKA — protein kinase A phosphorylates TRPV1 at S116, contributing to PGE2-mediated sensitization
- intraepidermal nerve fibre density — skin biopsy measure of small fiber neuropathy; TRPV1+ fibers are selectively vulnerable to oxylipin-mediated damage
- EPA — omega-3 fatty acid that competitively incorporates into membranes, reducing substrate for pro-nociceptive oxylipins
- DHA — omega-3 fatty acid that generates anti-inflammatory Resolvins and Protectins, opposing TRPV1 sensitization
- metaflammation — chronic Low-Grade Inflammation driven by metabolic dysfunction; TRPV1 activation contributes via neurogenic inflammation
- Visceral Hypersensitivity — enhanced visceral pain in IBS mediated by TRPV1 sensitization on enteric nervous system neurons
- Migraine — TRPV1 on Trigeminal nerve nociceptors activated by inflammation, calcitonin gene-related peptide (CGRP) release drives migraine pathophysiology